These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 12893752)

  • 1. NK-cell purging of leukemia: superior antitumor effects of NK cells H2 allogeneic to the tumor and augmentation with inhibitory receptor blockade.
    Koh CY; Ortaldo JR; Blazar BR; Bennett M; Murphy WJ
    Blood; 2003 Dec; 102(12):4067-75. PubMed ID: 12893752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NK inhibitory-receptor blockade for purging of leukemia: effects on hematopoietic reconstitution.
    Koh CY; Raziuddin A; Welniak LA; Blazar BR; Bennett M; Murphy WJ
    Biol Blood Marrow Transplant; 2002; 8(1):17-25. PubMed ID: 11846352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo.
    Koh CY; Blazar BR; George T; Welniak LA; Capitini CM; Raziuddin A; Murphy WJ; Bennett M
    Blood; 2001 May; 97(10):3132-7. PubMed ID: 11342440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determinants of antileukemia effects of allogeneic NK cells.
    Leung W; Iyengar R; Turner V; Lang P; Bader P; Conn P; Niethammer D; Handgretinger R
    J Immunol; 2004 Jan; 172(1):644-50. PubMed ID: 14688377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of natural killer cell-mediated bone marrow graft rejection by allogeneic major histocompatibility complex class I, but not class II molecules.
    Ohlén C; Höglund P; Sentman CL; Carbone E; Ljunggren HG; Koller B; Kärre K
    Eur J Immunol; 1995 May; 25(5):1286-91. PubMed ID: 7774631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
    Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
    Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of graft-versus-leukemia (GVL) activity in murine leukemia models after IL-2 pretreatment of syngeneic and allogeneic bone marrow grafts.
    Zeis M; Uharek L; Glass B; Gaska T; Gassmann W; Mueller-Ruchholtz W
    Bone Marrow Transplant; 1994 Nov; 14(5):711-5. PubMed ID: 7889004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells.
    Igarashi T; Wynberg J; Srinivasan R; Becknell B; McCoy JP; Takahashi Y; Suffredini DA; Linehan WM; Caligiuri MA; Childs RW
    Blood; 2004 Jul; 104(1):170-7. PubMed ID: 15016654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activated allogeneic NK cells as suppressors of alloreactive responses.
    Hu B; He Y; Wu Y; Bao G; Liu H; Welniak LA; Murphy WJ
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):772-81. PubMed ID: 20197103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mouse host unlicensed NK cells promote donor allogeneic bone marrow engraftment.
    Alvarez M; Sun K; Murphy WJ
    Blood; 2016 Mar; 127(9):1202-5. PubMed ID: 26738538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altered donor and recipient Ly49+ NK cell subsets in allogeneic H-2d --> H-2b and H-2b --> H-2d bone marrow chimeras.
    Korten S; Wilk E; Gessner JE; Meyer D; Schmidt RE
    J Immunol; 1999 Dec; 163(11):5896-905. PubMed ID: 10570275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of donor NK and T cells infused in patients undergoing MHC-matched allogeneic hematopoietic transplantation.
    Pascal V; Brunet C; Pradel V; Thirion X; Andre P; Faucher C; Sampol J; Dignat-George F; Blaise D; Vivier E; Chabannon C
    Leukemia; 2002 Nov; 16(11):2259-66. PubMed ID: 12399971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic MHC-mismatched activated natural killer cells administered after bone marrow transplantation provide a strong graft-versus-leukaemia effect in mice.
    Zeis M; Uharek L; Glass B; Steinmann J; Dreger P; Gassmann W; Schmitz N
    Br J Haematol; 1997 Mar; 96(4):757-61. PubMed ID: 9074419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mouse NK cell-mediated rejection of bone marrow allografts exhibits patterns consistent with Ly49 subset licensing.
    Sun K; Alvarez M; Ames E; Barao I; Chen M; Longo DL; Redelman D; Murphy WJ
    Blood; 2012 Feb; 119(6):1590-8. PubMed ID: 22184406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transgenic expression of the Ly49A natural killer cell receptor confers class I major histocompatibility complex (MHC)-specific inhibition and prevents bone marrow allograft rejection.
    Held W; Cado D; Raulet DH
    J Exp Med; 1996 Nov; 184(5):2037-41. PubMed ID: 8920892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.
    Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE
    Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of a lethally irradiated major histocompatibility complex nonrestricted cytotoxic T-cell line for effective purging of marrows containing lysis-sensitive or -resistant leukemic targets.
    Cesano A; Pierson G; Visonneau S; Migliaccio AR; Santoli D
    Blood; 1996 Jan; 87(1):393-403. PubMed ID: 8547668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
    Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
    J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autologous bone marrow purging by in situ IL-2 activation of endogenous killer cells.
    Margolin KA; Wright C; Forman SJ
    Leukemia; 1997 May; 11(5):723-8. PubMed ID: 9180298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Experimental study on IL-2- and IL-15 application in allogeneic hematopoietic stem cell transplantation].
    Chen GH; Wu DP; Sun AN; Yang MZ; Wang Y; Tang XW; Chang HR; Feng YF; Zhu ZL
    Zhonghua Xue Ye Xue Za Zhi; 2008 Aug; 29(8):526-30. PubMed ID: 19112915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.